logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
3/19/2019 7:43:35 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q2 20 Estimate To -0.85 From -0.78
3/19/2019 7:43:19 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q1 20 Estimate To -0.89 From -0.87
3/19/2019 7:43:03 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -3.66 From -3.63
3/19/2019 7:42:49 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q4 19 Estimate To -0.95 From -0.92
3/19/2019 7:42:02 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $76 Down From $80 Price Target
3/18/2019 8:04:35 AM FDA Accepts BLA Filing Of Aimmune Therapeutics’ AR101 For Peanut Allergy
2/5/2019 7:58:06 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $80 Price Target
1/4/2019 8:46:22 AM Aimmune Therapeutics Enters $170 Mln Loan Agreement With An Affiliate Of KKR
12/20/2018 8:05:35 AM Aimmune Therapeutics Announces IND Filing For AR201 For Egg Allergy And Supply Agreement With Michael Foods
11/18/2018 5:01:23 PM Aimmune Says Landmark PALISADE Trial Of AR101 Published In New England Journal Of Medicine
11/8/2018 8:10:23 AM Aimmune Therapeutics To Present Data On AR101 At 2018 ACAAI Annual Scientific Meeting
10/15/2018 8:05:22 AM Aimmune Reports Initiation Of Phase 2 Study With Regeneron, Sanofi Of AR101 With Adjunctive Dupilumab In Peanut-Allergic
8/9/2018 9:05:53 AM Wedbush Is Raising Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -2.72 From -2.73
8/9/2018 9:05:38 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY18 Estimate To -3.35 From -3.26
8/9/2018 9:05:18 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
6/11/2018 4:01:53 PM Aimmune Therapeutics Appoints Dr. Jayson Dallas As CEO
  
 
>